Cybrexa Therapeutics has expanded its Scientific Advisory Board with the appointments of Geoffrey Shapiro, M.D., Ph.D. Director, the Dana-Farber Cancer Institute and Timothy Yap MBBS, Ph.D., MRCP(UK), BSc (Hons), PgDip of The University of Texas MD Anderson Cancer Center.

Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors and DNA damaging agents (TSDs) that directly target the tumor microenvironment.

Per Hellsund, President & CEO of Cybrexa, said, “Cybrexa is currently at a major inflection point as we rapidly move toward entering the clinic with the first candidate generated from our paradigm-changing tumor-selective technology platform.”